The VERIFY study aim is to compare combination regimen with vildagliptin and metformin versus metformin treatment in treatment-naïve patients with type 2 diabetes. In this section you can explore the baseline characteristics, study rationale and study design of the 5-year ongoing VERIFY trial to understand how the results could help change the way diabetes is treated.
Find out who was included in the study and see how the trial population is truly representative of real-world newly diagnosed, ethnically diverse patients with type 2 diabetes.
Learn more about the first real-world study to investigate the long-term clinical benefits of early combination treatment versus standard care in patients newly diagnosed with type 2 diabetes in over 2000 patients and across 34 countries.
See how VERIFY is set to provide unique long-term data on the durability of glycaemic control, beta-cell function, insulin resistance, early progression of diabetic complications and health status in treatment with a vildagliptin plus metformin treatment combination.
VERIFY has the potential to improve the health status and future prospects of millions of people living, or yet to be diagnosed with type 2 diabetes. Find out more about this 5-year on-going Phase 4 trial investigating whether early treatment with a combination of vildagliptin and metformin in people newly diagnosed with type 2 diabetes can induce a durable glycaemic control with favourable outcomes.
Can extended glycaemic control extend beta-cell function and preserve the development of complications?
VERIFY has a unique and pragmatic study design that aims to confirm whether vildagliptin plus metformin together can induce tighter and longer glycaemic control alone followed by the stepwise addition of vildagliptin when glycaemia deteriorates – discover more in this bite sized summary of this real-world trial.